Drug Profile
Autologous bone marrow derived mesenchymal stem cell therapy - Celvive
Latest Information Update: 17 Feb 2022
Price :
$50
*
At a glance
- Originator Celvive
- Developer Cairo University; Celvive
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Spinal cord injuries
Most Recent Events
- 15 Feb 2022 No development reported - Phase-I/II for Spinal cord injuries in Egypt (Intrathecal) (Celvive's website, February 2022)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Spinal-cord-injuries in USA (Intrathecal, Injection)
- 01 Apr 2014 Efficacy data from a phase I/II trial in Spinal cord injuries released by Cairo University